Study Finds Omicron Subvariant BA.4.6 Can Evade Antibody Protection From COVID-19 Therapy Evusheld

CNN (9/7, Goodman) reports that the antibodies in Evusheld (tixagevimab and cilgavimab), “the only therapy available to protect people with reduced immune function against Covid-19, may lose their punch against the BA.4.6 subvariant,” according to finding...